{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:21:57Z","timestamp":1792876917882,"version":"4.5.0"},"reference-count":302,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide\/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes. Beyond their well-known efficacy in treating male erectile dysfunction (ED) and pulmonary arterial hypertension (PAH), a plethora of studies have unveiled their significance in the treatment of a myriad of other diseases, including cognitive functions, heart failure, multiple drug resistance in cancer therapy, immune diseases, systemic sclerosis and others. This comprehensive review aims to provide an updated assessment of the crucial role played by PDE5 inhibitors (PDE5-Is) as disease-modifying agents taking their limiting side effects into consideration. From a medicinal chemistry and drug discovery perspective, the published PDE5-Is over the last 10 years and their binding characteristics are systemically discussed, and advancement in properties is exposed. A persistent challenge encountered with these agents lies in their limited isozyme selectivity; considering this obstacle, this review also highlights the breakthrough development of the recently reported PDE5 allosteric inhibitors, which exhibit an unparalleled level of selectivity that was rarely achievable by competitive inhibitors. The implications and potential impact of these novel allosteric inhibitors are meticulously explored. Additionally, the concept of multi-targeted ligands is critically evaluated in relation to PDE5-Is by inspecting the broader spectrum of their molecular interactions and effects. The objective of this review is to provide insight into the design of potent, selective PDE5-Is and an overview of their biological function, limitations, challenges, therapeutic potentials, undergoing clinical trials, future prospects and emerging uses, thus guiding upcoming endeavors in both academia and industry within this domain.<\/jats:p>","DOI":"10.3390\/ph16091266","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:07:37Z","timestamp":1693994857000},"page":"1266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives"],"prefix":"10.3390","volume":"16","author":[{"given":"Ahmed K.","family":"ElHady","sequence":"first","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, New Administrative Capital, Cairo 11865, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia S.","family":"El-Gamil","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Pharmacy, Ahram Canadian University, Cairo 12451, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-4219","authenticated-orcid":false,"given":"Mohammad","family":"Abdel-Halim","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-261X","authenticated-orcid":false,"given":"Ashraf H.","family":"Abadi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: Molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2174\/138161206778343064","article-title":"Expression, distribution and regulation of phosphodiesterase 5","volume":"12","author":"Lin","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19681","DOI":"10.1074\/jbc.M115.653113","article-title":"The role of phosphodiesterase 12 (PDE12) as a negative regulator of the innate immune response and the discovery of antiviral inhibitors","volume":"290","author":"Wood","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0302-2838(03)00215-X","article-title":"Male erectile dysfunction and health-related quality of life","volume":"44","author":"Fernandez","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40618-015-0340-5","article-title":"Phosphodiesterase type 5 inhibitors: Back and forward from cardiac indications","volume":"39","author":"Corinaldesi","year":"2016","journal-title":"J. Endocrinol. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-1119(98)00303-5","article-title":"Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase","volume":"216","author":"Loughney","year":"1998","journal-title":"Gene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/138161209789207015","article-title":"Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?","volume":"15","author":"Dimitriadis","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_8","first-page":"527","article-title":"Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract","volume":"2011","author":"Kuczyk","year":"2011","journal-title":"Urin. Tract"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation\u2013contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0005-2728(99)00024-9","article-title":"Guanylate cyclase and the\u22c5 NO\/cGMP signaling pathway","volume":"1411","author":"Denninger","year":"1999","journal-title":"Biochim. Biophys. Acta (BBA)-Bioenerg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMsa063904","article-title":"Nitric oxide and cyclic GMP in cell signaling and drug development","volume":"355","author":"Murad","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/35004606","article-title":"Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase I\u03b2","volume":"404","author":"Schlossmann","year":"2000","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1242\/jcs.113.10.1671","article-title":"Rising behind NO: cGMP-dependent protein kinases","volume":"113","author":"Hofmann","year":"2000","journal-title":"J. Cell Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/156802607779941198","article-title":"The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary\/cardiovascular vessels","volume":"7","author":"Zhu","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1152\/jappl.2001.91.3.1421","article-title":"Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: From the regulation of tone to gene expression","volume":"91","author":"Lincoln","year":"2001","journal-title":"J. Appl. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in anti-platelet therapy","volume":"210","author":"Rondina","year":"2012","journal-title":"Antiplatelet Agents"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10157-021-02051-6","article-title":"Reno-protective effects of Phosphodiesterase 5 inhibitors","volume":"25","author":"Coskuner","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/mol.66.1.144","article-title":"Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation","volume":"66","author":"Blount","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.2013.799665","article-title":"An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors","volume":"14","author":"Bruzziches","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1756287212466282","article-title":"Avanafil for the treatment of erectile dysfunction: Initial data and clinical key properties","volume":"5","author":"Kedia","year":"2013","journal-title":"Ther. Adv. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/20786204.2014.10855345","article-title":"A review of phosphodiesterase type 5 inhibitors","volume":"56","author":"Schellack","year":"2014","journal-title":"S. Afr. Fam. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0091270005276847","article-title":"The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction","volume":"45","author":"Gupta","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ecp.13.16","article-title":"Phosphodiesterase inhibitors in clinical urology","volume":"6","author":"Kuczyk","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ucl.2005.08.001","article-title":"Phosphodiesterase-5 inhibition: The molecular biology of erectile function and dysfunction","volume":"32","author":"Francis","year":"2005","journal-title":"Urol. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/j.1939-4640.2003.tb02744.x","article-title":"Molecular Biology and Pharmacology of PDE-5\u2014Inhibitor Therapy for Erectile Dysfunction","volume":"24","author":"Corbin","year":"2003","journal-title":"J. Androl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0090-4295(02)01687-4","article-title":"The efficacy of sildenafil citrate (Viagra\u00ae) in clinical populations: An update","volume":"60","author":"Carson","year":"2002","journal-title":"Urology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0090-4295(03)00115-8","article-title":"Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial","volume":"61","author":"Hellstrom","year":"2003","journal-title":"Urology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1743-6109.2011.02629.x","article-title":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction","volume":"9","author":"Goldstein","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4103\/1008-682X.123670","article-title":"Avanafil for male erectile dysfunction: A systematic review and meta-analysis","volume":"16","author":"Cui","year":"2014","journal-title":"Asian J. Androl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1743-6109.2011.02611.x","article-title":"How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors","volume":"9","author":"Jannini","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1464-410X.2008.08267.x","article-title":"Tadalafil and vardenafil vs sildenafil: A review of patient-preference studies","volume":"103","author":"Mirone","year":"2009","journal-title":"BJU Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","article-title":"High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors","volume":"334","author":"Corbin","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.autrev.2010.02.012","article-title":"Phosphodiesterase inhibitors in the management of autoimmune disease","volume":"9","author":"Shenoy","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3909\/ricm0679","article-title":"Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease","volume":"15","author":"Nguyen","year":"2014","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2017.06.010","article-title":"Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro","volume":"810","author":"Yamamura","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1743-6109.2008.01014.x","article-title":"BASIC SCIENCE: The PDE5 Inhibitor Sildenafil Increases Circulating Endothelial Progenitor Cells and CXCR4 Expression","volume":"6","author":"Foresta","year":"2009","journal-title":"J. Sex. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1378\/chest.07-0592","article-title":"Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension","volume":"133","author":"Gilbert","year":"2008","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1185\/03007990903210066","article-title":"Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension","volume":"25","author":"Beardsworth","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_44","first-page":"e30","article-title":"Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases","volume":"16","author":"Kukreja","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1590\/S0100-879X2011007500085","article-title":"Sildenafil prevents the increase of extravascular lung water and pulmonary hypertension after meconium aspiration in newborn piglets","volume":"44","author":"Silvera","year":"2011","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_46","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jacc.2011.07.051","article-title":"Cardiac uses of phosphodiesterase-5 inhibitors","volume":"59","author":"Schwartz","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cardfail.2008.09.005","article-title":"Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure","volume":"15","author":"Stehlik","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1535370214547155","article-title":"Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension","volume":"240","author":"Bowles","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1164\/rccm.200406-804OC","article-title":"Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension","volume":"171","author":"Richalet","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11918-004-0004-y","article-title":"The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence","volume":"2","author":"McVary","year":"2004","journal-title":"Curr. Prostate Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/nau.2099","article-title":"Reliability of pelvic floor muscle strength measurement in elderly incontinent women","volume":"21","author":"Uher","year":"2002","journal-title":"Neurourol. Urodyn. Off. J. Int. Cont. Soc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MOU.0b013e328316c357","article-title":"Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: The best of both worlds","volume":"19","author":"Wong","year":"2009","journal-title":"Curr. Opin. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.eururo.2012.07.025","article-title":"Sildenafil effect on the human bladder involves the L-cysteine\/hydrogen sulfide pathway: A novel mechanism of action of phosphodiesterase type 5 inhibitors","volume":"62","author":"Fusco","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12950-015-0099-7","article-title":"The role of phosphodiesterase-5 inhibitors in prostatic inflammation: A review","volume":"12","author":"Peixoto","year":"2015","journal-title":"J. Inflamm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14656566.2019.1589452","article-title":"Tadalafil for the treatment of benign prostatic hyperplasia","volume":"20","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2012.07.141","article-title":"Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia","volume":"189","author":"Nomiya","year":"2013","journal-title":"J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1464-410X.2002.03040.x","article-title":"Sildenafil influences lower urinary tract symptoms","volume":"90","author":"Sairam","year":"2002","journal-title":"BJU Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","article-title":"Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"177","author":"McVary","year":"2007","journal-title":"J. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1464-410X.2009.08822.x","article-title":"Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment","volume":"105","author":"Roehrborn","year":"2010","journal-title":"BJU Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.juro.2009.11.014","article-title":"Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial","volume":"183","author":"Dmochowski","year":"2010","journal-title":"J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","article-title":"A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"53","author":"Stief","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1743-6109.2008.01109.x","article-title":"Efficacy and Safety of Combined Oral Therapy with Tadalafil andAlfuzosin: An Integrated Approach to the Management of Patientswith Lower Urinary Tract Symptoms and Erectile Dysfunction. Preliminary Report","volume":"6","author":"Liguori","year":"2009","journal-title":"J. Sex. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","article-title":"Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"51","author":"Kaplan","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","article-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"61","author":"Gacci","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00345-009-0484-z","article-title":"Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"28","author":"Tuncel","year":"2010","journal-title":"World J. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/j.1743-6109.2008.00940.x","article-title":"Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS\/BPH. Pilot study","volume":"5","author":"Bechara","year":"2008","journal-title":"J. Sex. Med."},{"key":"ref_71","first-page":"e923179-1","article-title":"Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials","volume":"26","author":"Guo","year":"2020","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"99179","DOI":"10.18632\/oncotarget.21837","article-title":"Phosphodiesterase type 5 and cancers: Progress and challenges","volume":"8","author":"Barone","year":"2017","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1078-0432.CCR-15-1900","article-title":"Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted TherapyPDE5 Enhances Breast Cancer Cell Invasive Potential","volume":"22","author":"Catalano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12020-015-0586-x","article-title":"PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells","volume":"50","author":"Sponziello","year":"2015","journal-title":"Endocrine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.sxmr.2015.10.004","article-title":"The role of PDE5 inhibitors and the NO\/cGMP pathway in cancer","volume":"4","author":"Peak","year":"2016","journal-title":"Sex. Med. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3332\/ecancer.2018.824","article-title":"Repurposing drugs in oncology (ReDO)\u2014Selective PDE5 inhibitors as anti-cancer agents","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2002-01-0075","article-title":"Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells","volume":"101","author":"Sarfati","year":"2003","journal-title":"Blood"},{"key":"ref_78","first-page":"3311","article-title":"Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo","volume":"5","author":"Mei","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0006-2952(02)01345-X","article-title":"Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve \u03b2-catenin and cyclin D1 down-regulation","volume":"64","author":"Li","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1940-6207.CAPR-11-0095","article-title":"Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt\/\u03b2-catenin\u2013mediated transcription in human breast tumor cells","volume":"4","author":"Tinsley","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1158\/0008-5472.CAN-04-1517","article-title":"Inhibition of extracellular-signal regulated kinases 1\/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites","volume":"64","author":"Rice","year":"2004","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbrc.2018.10.050","article-title":"Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2","volume":"505","author":"Aono","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_83","first-page":"3338","article-title":"Exisulind induction of apoptosis involves guanosine 3\u2032, 5\u2032-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated \u03b2-catenin","volume":"60","author":"Thompson","year":"2000","journal-title":"Cancer Res."},{"key":"ref_84","first-page":"4136","article-title":"Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase","volume":"6","author":"Soh","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-013-1134-0","article-title":"Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells","volume":"31","author":"Li","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/mol.113.090043","article-title":"PDE5 inhibitors enhance chemotherapy killing in gastrointestinal\/genitourinary cancer cells","volume":"85","author":"Booth","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-2006-957701","article-title":"Decursinol angelate: A cytotoxic and protein kinase C activating agent from the root of Angelica gigas","volume":"63","author":"Ahn","year":"1997","journal-title":"Planta Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ding, P.-R., Tiwari, A.K., Ohnuma, S., Lee, J.W., An, X., Dai, C.-L., Lu, Q.-S., Singh, S., Yang, D.-H., and Talele, T.T. (2011). The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1\/P-glycoprotein transporter. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019329"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1158\/0008-5472.CAN-10-3820","article-title":"Sildenafil reverses ABCB1-and ABCG2-mediated chemotherapeutic drug resistance","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2008.06.122","article-title":"PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model","volume":"1230","author":"Black","year":"2008","journal-title":"Brain Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Hu, J., Ljubimova, J.Y., Inoue, S., Konda, B., Patil, R., Ding, H., Espinoza, A., Wawrowsky, K.A., Patil, C., and Ljubimov, A.V. (2010). Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010108"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jcp.24843","article-title":"PDE5 inhibitors enhance celecoxib killing in multiple tumor types","volume":"230","author":"Booth","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1073\/pnas.1006965107","article-title":"Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction","volume":"107","author":"Das","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fonc.2018.00681","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors sensitize topoisomerase II inhibitors in killing prostate cancer through PDE5-independent impairment of HR and NHEJ DNA repair systems","volume":"8","author":"Chang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3389\/fonc.2020.01274","article-title":"Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling","volume":"10","author":"Hsu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/jcp.24961","article-title":"Nexavar\/Stivarga and viagra interact to kill tumor cells","volume":"230","author":"Tavallai","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"13464","DOI":"10.18632\/oncotarget.14562","article-title":"PDE5 inhibitors enhance the lethality of [pemetrexed+ sorafenib]","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/jcp.24977","article-title":"OSU-03012 and Viagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood brain barrier: Implications for anti-cancer therapies","volume":"230","author":"Chuckalovcak","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/carcin\/bgaa001","article-title":"Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2","volume":"41","author":"Chen","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-14-1716","article-title":"Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Califano","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1053\/j.gastro.2019.05.012","article-title":"Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms","volume":"157","author":"Huang","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s11010-020-03982-6","article-title":"Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma","volume":"476","author":"Chhonker","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e23100","DOI":"10.1002\/jbt.23100","article-title":"Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance","volume":"36","author":"Chhonker","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2016.05.010","article-title":"Phosphodiesterase 5\/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway","volume":"378","author":"Liu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/NDT.S2447","article-title":"Role of phosphodiesterase 5 in synaptic plasticity and memory","volume":"4","author":"Puzzo","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","article-title":"Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus","volume":"19","author":"Lu","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.2174\/0929867323666160812145454","article-title":"Targeting NO\/cGMP signaling in the CNS for neurodegeneration and Alzheimer\u2019s disease","volume":"23","author":"Lee","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/MCB.23.16.5726-5737.2003","article-title":"Activation of the phosphatidylinositol 3-kinase\/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis","volume":"23","author":"Kawasaki","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/cn3000907","article-title":"Phosphodiesterases as therapeutic targets for Alzheimer\u2019s disease","volume":"3","author":"Oyarzabal","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3109\/00207454.2010.520381","article-title":"Phoshphodiesterase-5 inhibitors: Novel weapons against Alzheimer\u2019s disease?","volume":"120","author":"Sabayan","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","article-title":"Sildenafil restores cognitive function without affecting \u03b2-amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"164","author":"Hervias","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-\u03b2 load in an Alzheimer\u2019s disease mouse model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","article-title":"Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice","volume":"250","author":"Zhang","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood\u2013brain barrier and reverses cognitive dysfunction in a mouse model of AD","volume":"64","author":"Ricobaraza","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.pbb.2004.09.019","article-title":"Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats","volume":"79","author":"Devan","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.nlm.2012.02.008","article-title":"Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms","volume":"97","author":"Reneerkens","year":"2012","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"625.e611","DOI":"10.1016\/j.neurobiolaging.2011.03.018","article-title":"Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model","volume":"33","author":"Orejana","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbr.2016.10.046","article-title":"Neuroprotective effects of sildenafil against oxidative stress and memory dysfunction in mice exposed to noise stress","volume":"319","author":"Sikandaner","year":"2017","journal-title":"Behav. Brain Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2014.10.026","article-title":"Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice","volume":"745","author":"Hasan","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.brainresbull.2019.09.001","article-title":"Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer\u2019s disease","volume":"153","author":"Liu","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"113818","DOI":"10.1016\/j.bcp.2020.113818","article-title":"Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer\u2019s disease","volume":"176","author":"Zuccarello","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2006.08.028","article-title":"Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke","volume":"1118","author":"Zhang","year":"2006","journal-title":"Brain Res."},{"key":"ref_125","first-page":"1012","article-title":"Phosphodiesterase inhibition as a therapeutic target for brain ischemia","volume":"14","author":"Prickaerts","year":"2015","journal-title":"CNS Neurol. Disord.-Drug Targets (Former. Curr. Drug Targets-CNS Neurol. Disord.)"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cellsig.2017.06.015","article-title":"Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies","volume":"38","author":"Marlet","year":"2017","journal-title":"Cell. Signal."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.01.007","article-title":"Sildenafil treatment of subacute ischemic stroke: A safety study at 25-mg daily for 2 weeks","volume":"18","author":"Silver","year":"2009","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/14767058.2010.492061","article-title":"Effects of sildenafil and tadalafil on ischemia\/reperfusion injury in fetal rat brain","volume":"24","author":"Ozdegirmenci","year":"2011","journal-title":"J. Matern.-Fetal Neonatal Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.jcbfm.9600112","article-title":"Activation of the PI3-K\/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone","volume":"25","author":"Wang","year":"2005","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"878397","DOI":"10.1155\/2014\/878397","article-title":"Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5","volume":"2014","author":"Santos","year":"2014","journal-title":"Stem Cells Int."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2018.04.128","article-title":"Sildenafil protects neuronal cells from mitochondrial toxicity induced by \u03b2-amyloid peptide via ATP-sensitive K+ channels","volume":"500","author":"Son","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejphar.2013.06.035","article-title":"Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats","volume":"714","author":"Thakur","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/acn3.541","article-title":"Phosphodiesterase-5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury","volume":"5","author":"Kenney","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.expneurol.2015.10.013","article-title":"Phosphodiesterase-5 inhibition promotes remyelination by MCP-1\/CCR-2 and MMP-9 regulation in a cuprizone-induced demyelination model","volume":"275","author":"Verinaud","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00401-010-0795-6","article-title":"Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis","volume":"121","author":"Pifarre","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11011-012-9284-z","article-title":"Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats","volume":"27","author":"Liebenberg","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1134\/S1819712415040121","article-title":"Antidepressant-like effect of tadalafil, a phosphodiesterase type 5 inhibitor, in the forced swim test: Dose and duration of treatment dependence","volume":"9","author":"Otari","year":"2015","journal-title":"Neurochem. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2011.11.001","article-title":"Antidepressant-like effect of sildenafil through oxytocin-dependent cyclic AMP response element-binding protein phosphorylation","volume":"200","author":"Matsushita","year":"2012","journal-title":"Neuroscience"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nm.2634","article-title":"cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function","volume":"18","author":"Jaumann","year":"2012","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3349\/ymj.2010.51.1.82","article-title":"Effect of sildenafil on neuropathic pain and hemodynamics in rats","volume":"51","author":"Huang","year":"2010","journal-title":"Yonsei Med. J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2147\/JPR.S295265","article-title":"Antinociceptive Effect of Lodenafil Carbonate in Rodent Models of Inflammatory Pain and Spinal Nerve Ligation-Induced Neuropathic Pain","volume":"14","author":"Vieira","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.neuroscience.2011.07.039","article-title":"Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice","volume":"193","author":"Wang","year":"2011","journal-title":"Neuroscience"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1742-1241.2006.01087.x","article-title":"PDE5 inhibitors in diabetic peripheral neuropathy","volume":"60","author":"Hackett","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1472-8206.2007.00474.x","article-title":"Chronic neuropathic pain: Mechanisms, drug targets and measurement","volume":"21","author":"Finnerup","year":"2007","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro","volume":"83","author":"Wallis","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bph.13749","article-title":"Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia\/reperfusion injury and for treating heart failure","volume":"175","author":"Radovits","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10557-005-6894-2","article-title":"Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model","volume":"19","author":"Rossouw","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.ijir.3901497","article-title":"The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size","volume":"19","author":"Sesti","year":"2007","journal-title":"Int. J. Impot. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"H387","DOI":"10.1152\/ajpheart.00169.2009","article-title":"Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury","volume":"297","author":"Ahmad","year":"2009","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/bjp.2008.71","article-title":"Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG","volume":"154","author":"Maas","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"12944","DOI":"10.1074\/jbc.M404706200","article-title":"Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: Essential role of nitric oxide signaling","volume":"280","author":"Das","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1172\/JCI70731","article-title":"PDE5 inhibitor efficacy is estrogen dependent in female heart disease","volume":"124","author":"Sasaki","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/stem.789","article-title":"Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice","volume":"30","author":"Hoke","year":"2012","journal-title":"Stem Cells"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1161\/CIRCULATIONAHA.108.843979","article-title":"Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia\/reperfusion through protein-kinase G\u2013dependent generation of hydrogen sulfide","volume":"120","author":"Salloum","year":"2009","journal-title":"Circulation"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11010-020-03710-0","article-title":"Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: Role of nitric oxide","volume":"468","author":"Koka","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","article-title":"Phosphodiesterase-5 inhibitors and the heart: Compound cardioprotection?","volume":"104","author":"Hutchings","year":"2018","journal-title":"Heart"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","article-title":"Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility","volume":"116","author":"Nagendran","year":"2007","journal-title":"Circulation"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.clpt.6100306","article-title":"Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients","volume":"83","author":"Guazzi","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.14740\/jocmr3008w","article-title":"Phosphodiesterase-5 inhibitors improve clinical outcomes, exercise capacity and pulmonary hemodynamics in patients with heart failure with reduced left ventricular ejection fraction: A meta-analysis","volume":"9","author":"Cesaro","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect","volume":"334","author":"Koka","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000279307","article-title":"Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension","volume":"31","author":"Yaguas","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2012.05.015","article-title":"Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts","volume":"690","author":"Lee","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bjp.0705658","article-title":"Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs","volume":"141","author":"Nagy","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0003319710362977","article-title":"Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: A pilot study","volume":"61","author":"Bonanni","year":"2010","journal-title":"Angiology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjp.2008.141","article-title":"Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets","volume":"154","author":"Toque","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jacc.2005.11.060","article-title":"Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis","volume":"47","author":"Lewis","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e004222","DOI":"10.1161\/CIRCHEARTFAILURE.117.004222","article-title":"Sildenafil is associated with reduced device thrombosis and ischemic stroke despite low-level hemolysis on Heart Mate II support","volume":"10","author":"Saeed","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bbrc.2005.09.060","article-title":"Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation","volume":"337","author":"McRobbie","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"key":"ref_172","first-page":"1918","article-title":"Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud\u2019s phenomenon in patients with systemic sclerosis: A potential treatment","volume":"33","author":"Kumar","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.sxmr.2018.03.008","article-title":"Cardiovascular safety of phosphodiesterase type 5 inhibitors after nearly 2 decades on the market","volume":"6","author":"Kloner","year":"2018","journal-title":"Sex. Med. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.bjp.0707132","article-title":"Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase","volume":"150","author":"Kukreja","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yjmcc.2005.10.002","article-title":"Vardenafil: A novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia\/reperfusion injury via opening of mitochondrial KATP channels in rabbits","volume":"40","author":"Salloum","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yjmcc.2007.10.006","article-title":"Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection","volume":"44","author":"Wang","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"H827","DOI":"10.1152\/ajpheart.00129.2010","article-title":"Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury","volume":"299","author":"Madhani","year":"2010","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.yjmcc.2011.02.013","article-title":"cGMP\/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion","volume":"50","author":"Inserte","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jacc.2008.08.069","article-title":"Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload","volume":"53","author":"Nagayama","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2741\/4450","article-title":"PDE5 inhibitors protect against post-infarction heart failure","volume":"21","author":"Li","year":"2016","journal-title":"Front. Biosci.-Landmark"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"H2272","DOI":"10.1152\/ajpheart.00654.2010","article-title":"Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA\/Rho-kinase pathway","volume":"300","author":"Chau","year":"2011","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11255-015-1071-4","article-title":"Phosphodiesterase type 5 inhibitors and kidney disease","volume":"47","author":"Afsar","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1590\/1806-9282.65.3.388","article-title":"Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction","volume":"65","author":"Benli","year":"2019","journal-title":"Rev. Da Assoc. M\u00e9dica Bras."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphar.2012.00167","article-title":"PDE5 inhibitors as potential tools in the treatment of cystic fibrosis","volume":"3","author":"Noel","year":"2012","journal-title":"Front. Pharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1183\/09031936.00013510","article-title":"Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice","volume":"37","author":"Lubamba","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2040622319887879","DOI":"10.1177\/2040622319887879","article-title":"Sildenafil improves exercise capacity in patients with cystic fibrosis: A proof-of-concept clinical trial","volume":"10","author":"Ishii","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/thx.2003.019778","article-title":"Sildenafil (Viagra) corrects \u0394F508-CFTR location in nasal epithelial cells from patients with cystic fibrosis","volume":"60","author":"Dormer","year":"2005","journal-title":"Thorax"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1164\/rccm.200703-344OC","article-title":"Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis","volume":"177","author":"Lubamba","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Dhooghe, B., No\u00ebl, S., Bouzin, C., Behets-Wydemans, G., and Leal, T. (2013). Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077314"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"L712","DOI":"10.1152\/ajplung.00314.2006","article-title":"Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis","volume":"293","author":"Poschet","year":"2007","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1042\/CS20160749","article-title":"Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5-and CFTR-dependent mechanisms","volume":"131","author":"Noel","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.embor.7400674","article-title":"Endosomal hyperacidification in cystic fibrosis is due to defective nitric oxide\u2013cylic GMP signalling cascade","volume":"7","author":"Poschet","year":"2006","journal-title":"EMBO Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"H1486","DOI":"10.1152\/ajpheart.00301.2018","article-title":"Sildenafil improves vascular endothelial function in patients with cystic fibrosis","volume":"315","author":"Lee","year":"2018","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11010-022-04520-2","article-title":"Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine\u2014A possible prevention strategy for COVID-19?","volume":"479","author":"Kukreja","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0022-5347(05)64174-2","article-title":"A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation","volume":"168","author":"Salonia","year":"2002","journal-title":"J. Urol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1464-410X.2010.09646.x","article-title":"The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: A double-blind laboratory setting study","volume":"107","author":"Halis","year":"2011","journal-title":"BJU Int."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1464-410X.2006.06290.x","article-title":"Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review","volume":"98","author":"Mcmahon","year":"2006","journal-title":"BJU Int."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","article-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease","volume":"97","author":"Ferrini","year":"2006","journal-title":"BJU Int."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie\u2019s disease with PDE5 inhibitors: An antifibrotic strategy","volume":"7","author":"Rajfer","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1745-7262.2008.00373.x","article-title":"Effects of phosphodiesterase 5 inhibitors on sperm parameters and fertilizing capacity","volume":"10","author":"Dimitriadis","year":"2008","journal-title":"Asian J. Androl."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.fertnstert.2003.08.032","article-title":"Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate","volume":"81","author":"Jannini","year":"2004","journal-title":"Fertil. Steril."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.1152\/ajpendo.00337.2010","article-title":"Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP\/cGMP signaling pathway","volume":"299","author":"Andric","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/j.1743-6109.2012.02674.x","article-title":"Transient rise of serum testosterone level after single sildenafil treatment of adult male rats","volume":"9","author":"Janjic","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14767058.2019.1624717","article-title":"Phase-1 clinical study of tadalafil administered for selective fetal growth restriction in twin pregnancy","volume":"34","author":"Magawa","year":"2021","journal-title":"J. Matern.-Fetal Neonatal Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/andr.12837","article-title":"Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project","volume":"9","author":"Isidori","year":"2021","journal-title":"Andrology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/17512433.2016.1212655","article-title":"Avanafil for the treatment of erectile dysfunction","volume":"9","author":"Zurawin","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: A prospective cohort study","volume":"174","author":"Li","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2015.6604","article-title":"Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma","volume":"313","author":"Loeb","year":"2015","journal-title":"JAMA"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bjc.2016.248","article-title":"Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma","volume":"115","author":"Schmidt","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/14740338.2019.1659244","article-title":"An update on the drug safety of treating erectile dysfunction","volume":"18","author":"Gul","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1442-9071.2009.02070.x","article-title":"Phosphodiesterase inhibitors and the eye","volume":"37","author":"Kerr","year":"2009","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jsm.12726","article-title":"Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors","volume":"12","author":"Campbell","year":"2015","journal-title":"J. Sex. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urology.2017.02.044","article-title":"Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure","volume":"105","author":"Flahavan","year":"2017","journal-title":"Urology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1248\/bpb.31.1981","article-title":"High dosage sildenafil induces hearing impairment in mice","volume":"31","author":"Hong","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.amjoto.2012.04.005","article-title":"Histopathologic results of long-term sildenafil administration on rat inner ear","volume":"33","author":"Bakir","year":"2012","journal-title":"Am. J. Otolaryngol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lary.21450","article-title":"Viagra deafness\u2014Sensorineural hearing loss and phosphodiesterase-5 inhibitors","volume":"121","author":"Khan","year":"2011","journal-title":"Laryngoscope"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/lary.20511","article-title":"Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology","volume":"119","author":"Maddox","year":"2009","journal-title":"Laryngoscope"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1743-6109.2009.01625.x","article-title":"Priapism: Pathogenesis, epidemiology, and management","volume":"7","author":"Broderick","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.mayocp.2012.06.015","article-title":"The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease","volume":"87","author":"Nehra","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14756366.2016.1250756","article-title":"Investigation of PDE5\/PDE6 and PDE5\/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development","volume":"32","author":"Durdagi","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0094-0143(05)70141-5","article-title":"Oral drug therapy for erectile dysfunction","volume":"28","author":"Giuliano","year":"2001","journal-title":"Urol. Clin. N. Am."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/0960-894X(96)00323-X","article-title":"Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction","volume":"6","author":"Terrett","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0960-894X(02)00030-6","article-title":"Imidazo [5, 1-f], triazin-4 (3H)-ones, a new class of potent PDE 5 inhibitors","volume":"12","author":"Haning","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ucl.2007.08.013","article-title":"Phosphodiesterase type 5 inhibitors: State of the therapeutic class","volume":"34","author":"Carson","year":"2007","journal-title":"Urol. Clin. N. Am."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ncpuro0186","article-title":"Drug insight: Oral phosphodiesterase type 5 inhibitors for erectile dysfunction","volume":"2","author":"Briganti","year":"2005","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1021\/jm030056e","article-title":"The discovery of Tadalafil: A novel and highly selective PDE5 inhibitor. 1: 5, 6, 11, 11a-Tetrahydro-1 H-imidazo [1\u2032, 5\u2032: 1, 6] pyrido [3, 4-b] indole-1, 3 (2 H)-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/jm0300577","article-title":"The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 2: 2, 3, 6, 7, 12, 12a-hexahydropyrazino [1\u2032, 2\u2032: 1, 6] pyrido [3, 4-b] indole-1, 4-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1021\/jm301159y","article-title":"Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5","volume":"55","author":"Wang","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1016\/j.bmcl.2013.06.062","article-title":"Exploration of the 5-bromopyrimidin-4 (3H)-ones as potent inhibitors of PDE5","volume":"23","author":"Gong","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1016\/j.bmcl.2014.09.082","article-title":"Design and synthesis of novel 5-(3, 4, 5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: Scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation","volume":"24","author":"Sakamoto","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1016\/j.bmcl.2014.10.008","article-title":"The discovery of avanafil for the treatment of erectile dysfunction: A novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor","volume":"24","author":"Sakamoto","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bmcl.2015.02.041","article-title":"8-(3-Chloro-4-methoxybenzyl)-8H-pyrido [2, 3-d] pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors","volume":"25","author":"Sakamoto","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.bmc.2015.03.005","article-title":"Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5","volume":"23","author":"Sawant","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"103022","DOI":"10.1016\/j.bioorg.2019.103022","article-title":"Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction","volume":"89","author":"Reddy","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bmc.2011.10.022","article-title":"The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics","volume":"20","author":"Rawson","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ddr.21493","article-title":"Tadalafil: 15 years\u2019 journey in male erectile dysfunction and beyond","volume":"80","author":"Ahmed","year":"2019","journal-title":"Drug Dev. Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ardp.201200334","article-title":"Design of novel \u03b2-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors","volume":"346","author":"Ahmed","year":"2013","journal-title":"Arch. Der Pharm."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/scipharm84030428","article-title":"Structure-based design of novel tetrahydro-beta-carboline derivatives with a hydrophilic side chain as potential phosphodiesterase inhibitors","volume":"84","author":"Elhady","year":"2016","journal-title":"Sci. Pharm."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ejmech.2018.09.028","article-title":"Discovery of furyl\/thienyl \u03b2-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect","volume":"158","author":"Zheng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejmech.2012.09.029","article-title":"Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel \u03b2-carboline derivatives","volume":"57","author":"Ahmed","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ardp.201000236","article-title":"Design, Synthesis and Structure\u2013Activity Relationship of Functionalized Tetrahydro-\u03b2-carboline Derivatives as Novel PDE5 Inhibitors","volume":"344","author":"Ahmed","year":"2011","journal-title":"Arch. Der Pharm."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1021\/jm00039a024","article-title":"Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity","volume":"37","author":"Takase","year":"1994","journal-title":"J. Med. Chem."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/jm00018a014","article-title":"Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl-and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities","volume":"38","author":"Lee","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"117092","DOI":"10.1016\/j.bmc.2022.117092","article-title":"Computational design, synthesis and biological evaluation of PDE5 inhibitors based on N2, N4-diaminoquinazoline and N2, N6-diaminopurine scaffolds","volume":"76","author":"Somnarin","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bmcl.2018.11.043","article-title":"Design, synthesis and evaluation of N2, N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5","volume":"29","author":"Pobsuk","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"107111","DOI":"10.1016\/j.vph.2022.107111","article-title":"Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects","volume":"147","author":"Chatturong","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"127097","DOI":"10.1016\/j.bmcl.2020.127097","article-title":"Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer\u2019s disease","volume":"30","author":"Huang","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejmech.2018.02.039","article-title":"Design and synthesis of furyl\/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors","volume":"150","author":"Zheng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejmech.2012.12.009","article-title":"Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer\u2019s disease","volume":"60","author":"Fiorito","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/acs.jmedchem.7b00979","article-title":"Identification of a novel 1, 2, 3, 4-tetrahydrobenzo [b][1, 6] naphthyridine analogue as a potent phosphodiesterase 5 inhibitor with improved aqueous solubility for the treatment of Alzheimer\u2019s disease","volume":"60","author":"Fiorito","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2014.02.013","article-title":"Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl) chromeno [2, 3-c] pyrrol-9 (2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure","volume":"89","author":"Shang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1021\/acs.jmedchem.7b00523","article-title":"Discovery and optimization of chromeno [2, 3-c] pyrrol-9 (2 H)-ones as novel selective and orally bioavailable phosphodiesterase 5 inhibitors for the treatment of pulmonary arterial hypertension","volume":"60","author":"Wu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/acs.jmedchem.8b01209","article-title":"Optimization of Chromeno [2, 3-c] pyrrol-9 (2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure\u2013Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.apsb.2021.09.027","article-title":"Free energy perturbation (FEP)-guided scaffold hopping","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Amin, K.M., El-Badry, O.M., Abdel Rahman, D.E., Abdellattif, M.H., Abourehab, M.A., El-Maghrabey, M.H., Elsaid, F.G., El Hamd, M.A., Elkamhawy, A., and Ammar, U.M. (2022). Scaffold repurposing reveals new nanomolar phosphodiesterase type 5 (PDE5) inhibitors based on pyridopyrazinone scaffold: Investigation of in vitro and in silico properties. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091954"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1016\/j.bmcl.2009.06.012","article-title":"Identification, synthesis and SAR of amino substituted pyrido [3, 2b] pyrazinones as potent and selective PDE5 inhibitors","volume":"19","author":"Owen","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.bmcl.2009.06.004","article-title":"Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system","volume":"19","author":"Hughes","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1800018","DOI":"10.1002\/ardp.201800018","article-title":"Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors","volume":"351","author":"Lee","year":"2018","journal-title":"Arch. Der Pharm."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1021\/acs.jmedchem.0c00983","article-title":"Discovery of evodiamine derivatives as highly selective PDE5 inhibitors targeting a unique allosteric pocket","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/acs.jmedchem.0c01120","article-title":"From celecoxib to a novel class of phosphodiesterase 5 inhibitors: Trisubstituted pyrazolines as novel phosphodiesterase 5 inhibitors with extremely high potency and phosphodiesterase isozyme selectivity","volume":"64","author":"Sigler","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1021\/acs.jmedchem.6b00908","article-title":"Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"59","author":"Rabal","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acschemneuro.6b00370","article-title":"Impact of scaffold exploration on novel dual-acting histone deacetylases and phosphodiesterase 5 inhibitors for the treatment of Alzheimer\u2019s disease","volume":"8","author":"Rabal","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1021\/acschemneuro.8b00648","article-title":"Discovery of in vivo chemical probes for treating Alzheimer\u2019s disease: Dual phosphodiesterase 5 (PDE5) and class I histone deacetylase selective inhibitors","volume":"10","author":"Rabal","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejmech.2018.03.005","article-title":"Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer\u2019s disease","volume":"150","author":"Rabal","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/npp.2016.163","article-title":"A first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer\u2019s disease mice","volume":"42","author":"Rabal","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"Claveria-Cabello, A., Colyn, L., Uriarte, I., Latasa, M.U., Arechederra, M., Herranz, J.M., Alvarez, L., Urman, J.M., Martinez-Chantar, M.L., and Banales, J.M. (2020). Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 12.","DOI":"10.3390\/cancers12123748"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1568026615666150813145629","article-title":"Selective histone deacetylase inhibitors with anticancer activity","volume":"16","author":"Ma","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"103742","DOI":"10.1016\/j.bioorg.2020.103742","article-title":"Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors","volume":"98","author":"ElHady","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/acschemneuro.7b00345","article-title":"Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer\u2019s disease","volume":"9","author":"Mao","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jid.2020.05.111","article-title":"A dual-acting nitric oxide donor and phosphodiesterase 5 inhibitor promotes wound healing in normal mice and mice with diabetes","volume":"141","author":"Greenwald","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Ammar, L., Lin, H.-Y., Shih, S.-P., Tsai, T.-N., Syu, Y.-T., Abdel-Halim, M., Hwang, T.-L., and Abadi, A.H. (2023). Novel 9-Benzylaminoacridine Derivatives as Dual Inhibitors of Phosphodiesterase 5 and Topoisomerase II for the Treatment of Colon Cancer. Molecules, 28.","DOI":"10.3390\/molecules28020840"},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Liu, J., Wenzel, B., Dukic-Stefanovic, S., Teodoro, R., Ludwig, F.-A., Deuther-Conrad, W., Schr\u00f6der, S., Chezal, J.-M., Moreau, E., and Brust, P. (2016). Development of a new radiofluorinated quinoline analog for PET imaging of phosphodiesterase 5 (PDE5) in brain. Pharmaceuticals, 9.","DOI":"10.3390\/ph9020022"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nucmedbio.2013.10.007","article-title":"Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5)","volume":"41","author":"Chekol","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acs.jmedchem.6b01666","article-title":"Carbon-11 and fluorine-18 radiolabeled pyridopyrazinone derivatives for positron emission tomography (PET) imaging of phosphodiesterase-5 (PDE5)","volume":"60","author":"Chekol","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejmech.2017.03.091","article-title":"Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes","volume":"136","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"109190","DOI":"10.1016\/j.apradiso.2020.109190","article-title":"Radiosynthesis of a carbon-11 labeled PDE5 inhibitor [11C] TPN171 as a new potential PET heart imaging agent","volume":"162","author":"Xu","year":"2020","journal-title":"Appl. Radiat. Isot."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41401-022-00922-6","article-title":"Pharmacokinetics, mass balance, and metabolism of [14C] TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension","volume":"44","author":"He","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bioorg.2019.01.037","article-title":"Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18","volume":"86","author":"Wenzel","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"108873","DOI":"10.1016\/j.apradiso.2019.108873","article-title":"Radiosynthesis of carbon-11 labeled PDE5 inhibitors as new potential PET radiotracers for imaging of Alzheimer\u2019s disease","volume":"154","author":"Dong","year":"2019","journal-title":"Appl. Radiat. Isot."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"110160","DOI":"10.1016\/j.apradiso.2022.110160","article-title":"Preparation and evaluation of radioiodinated avanafil: A novel potential radiopharmaceutical for the diagnostic evaluation of erectile dysfunction","volume":"183","author":"Ibrahim","year":"2022","journal-title":"Appl. Radiat. Isot."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1021\/bi7010702","article-title":"Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors","volume":"46","author":"Zoraghi","year":"2007","journal-title":"Biochemistry"},{"key":"ref_283","first-page":"273","article-title":"The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension","volume":"6","author":"Falk","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1345\/aph.1R528","article-title":"Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms","volume":"47","author":"Miller","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.2174\/138161212803307554","article-title":"PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update","volume":"18","author":"Gur","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s43440-021-00349-6","article-title":"How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme","volume":"74","author":"Sanati","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10557-021-07275-y","article-title":"Cardiac effects of phosphodiesterase-5 inhibitors: Efficacy and safety","volume":"37","author":"Roy","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"e205323","DOI":"10.1001\/jamanetworkopen.2020.5323","article-title":"Maternal sildenafil vs placebo in pregnant women with severe early-onset fetal growth restriction: A randomized clinical trial","volume":"3","author":"Pels","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: Post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1078-0432.CCR-21-1816","article-title":"Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma","volume":"28","author":"Luginbuhl","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.clinthera.2019.05.006","article-title":"Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: A placebo-controlled, double-blind, phase IIb clinical trial","volume":"41","author":"Chang","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-021-03885-y","article-title":"Sildenafil for treating patients with COVID-19 and perfusion mismatch: A pilot randomized trial","volume":"26","author":"Santamarina","year":"2022","journal-title":"Crit. Care"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"e022126","DOI":"10.1161\/JAHA.121.022126","article-title":"Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre\u2013Heart Failure","volume":"11","author":"Hubers","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40262-021-01052-8","article-title":"Population pharmacokinetics of tadalafil in pediatric patients with pulmonary arterial hypertension: A combined adult\/pediatric model","volume":"61","author":"Li","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"106563","DOI":"10.1016\/j.vph.2019.05.003","article-title":"Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study","volume":"118","author":"Omarjee","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ejhf.2924","article-title":"Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function\u2014A multi-center, double-blind, randomized, placebo-controlled trial\u2013SERVE","volume":"25","author":"Greutmann","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12072-021-10264-w","article-title":"Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: A randomized double blind placebo controlled trial","volume":"17","author":"Jagdish","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_299","first-page":"e013676","article-title":"Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants","volume":"15","author":"Goldberg","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Andersen, A., Waziri, F., Schultz, J.G., Holmboe, S., Becker, S.W., Jensen, T., S\u00f8ndergaard, H.M., Dodt, K.K., May, O., and Mortensen, U.M. (2021). Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: A randomized explorative trial. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01440-7"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jpeds.2021.05.051","article-title":"Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): A multicenter, randomized, placebo-controlled trial","volume":"237","author":"Pierce","year":"2021","journal-title":"J. Pediatr."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1249\/MSS.0000000000002521","article-title":"Exercise intolerance in cystic fibrosis: Importance of skeletal muscle","volume":"53","author":"Seigler","year":"2021","journal-title":"Med. Sci. Sports Exerc."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/9\/1266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:46:22Z","timestamp":1760129182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/9\/1266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":302,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ph16091266"],"URL":"https:\/\/doi.org\/10.3390\/ph16091266","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}